Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?

Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21

Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med (1999) 6.50

Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48

Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med (2008) 5.20

Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA (1998) 4.73

The idolatry of the surrogate. BMJ (2011) 3.81

Modelling in economic evaluation: an unavoidable fact of life. Health Econ (1997) 3.40

Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol (2005) 2.83

Is sexual contact a major mode of hepatitis C virus transmission? Hepatology (2010) 2.58

Clinical practice. Chronic hepatitis C infection. N Engl J Med (2011) 2.54

Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev (2000) 2.45

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology (2003) 2.05

Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health (2008) 2.05

Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion (2009) 2.00

Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA (1999) 1.84

Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med (2012) 1.80

The history of the "natural history" of hepatitis C (1968-2009). Liver Int (2009) 1.63

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2010) 1.58

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology (2011) 1.30

Evidence at a glance: error matrix approach for overviewing available evidence. BMC Med Res Methodol (2010) 1.16

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology (2000) 1.12

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol (2004) 1.12

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer (2000) 1.08

Hepatology may have problems with putative surrogate outcome measures. J Hepatol (2007) 1.01

Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis (2010) 0.98

Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.98

Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev (2002) 0.93

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Dig Dis Sci (2011) 0.91

Natural history of acute symptomatic hepatitis type C. Infection (2004) 0.88

Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol (2012) 0.87

Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat (2009) 0.87

Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand J Infect Dis (2005) 0.87

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev (2013) 0.82

Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev (2010) 0.81

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One (2012) 0.77